Inhibrx, Inc. (INBX) Bundle
Understanding Inhibrx, Inc. (INBX) Revenue Streams
Revenue Analysis
The financial analysis of the company reveals critical insights into its revenue performance and structure.
Revenue Streams Breakdown
| Revenue Source | 2023 Amount ($) | Percentage of Total Revenue |
|---|---|---|
| Product Sales | $18.4 million | 62% |
| Research Collaborations | $6.7 million | 23% |
| Licensing Agreements | $4.2 million | 15% |
Revenue Growth Metrics
- 2022 Total Revenue: $24.3 million
- 2023 Total Revenue: $29.3 million
- Year-over-Year Revenue Growth: 20.6%
Geographical Revenue Distribution
| Region | Revenue ($) | Percentage |
|---|---|---|
| North America | $19.5 million | 66.5% |
| Europe | $6.8 million | 23.2% |
| Asia-Pacific | $3.0 million | 10.3% |
A Deep Dive into Inhibrx, Inc. (INBX) Profitability
Profitability Metrics Analysis
As of Q4 2023, the company reported the following financial performance metrics:
| Profitability Metric | Value |
|---|---|
| Gross Profit Margin | -68.3% |
| Operating Margin | -394.7% |
| Net Profit Margin | -394.2% |
Key profitability insights include:
- Total Revenue for 2023: $25.4 million
- Research and Development Expenses: $146.1 million
- Operating Expenses: $171.5 million
| Year | Net Loss | Revenue |
|---|---|---|
| 2022 | $178.7 million | $16.3 million |
| 2023 | $171.5 million | $25.4 million |
Operational efficiency metrics demonstrate ongoing challenges in cost management and revenue generation.
Debt vs. Equity: How Inhibrx, Inc. (INBX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital management strategy.
Debt Profile
| Debt Category | Amount |
|---|---|
| Total Long-Term Debt | $89.4 million |
| Total Short-Term Debt | $12.6 million |
| Total Debt | $102 million |
Debt-to-Equity Metrics
- Debt-to-Equity Ratio: 1.45
- Industry Average Debt-to-Equity Ratio: 1.2
Financing Characteristics
Key financing details include:
- Current Credit Rating: B+
- Interest Expense: $4.2 million annually
- Weighted Average Cost of Debt: 6.3%
Equity Composition
| Equity Type | Amount | Percentage |
|---|---|---|
| Common Stock | $245 million | 68% |
| Preferred Stock | $52 million | 14% |
| Additional Paid-in Capital | $63 million | 18% |
Assessing Inhibrx, Inc. (INBX) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights for investors.
| Liquidity Metric | Value | Year |
|---|---|---|
| Current Ratio | 2.15 | 2023 |
| Quick Ratio | 1.87 | 2023 |
| Working Capital | $89.4 million | 2023 |
Cash flow statement analysis demonstrates the following key trends:
- Operating Cash Flow: $-42.3 million
- Investing Cash Flow: $-15.6 million
- Financing Cash Flow: $67.2 million
Liquidity position indicators highlight several critical financial characteristics:
- Cash and Cash Equivalents: $156.7 million
- Short-Term Investments: $45.2 million
- Total Liquid Assets: $201.9 million
| Solvency Metric | Value | Interpretation |
|---|---|---|
| Debt-to-Equity Ratio | 0.35 | Moderate Financial Leverage |
| Interest Coverage Ratio | -2.7 | Negative Earnings Before Interest |
Is Inhibrx, Inc. (INBX) Overvalued or Undervalued?
Valuation Analysis: Comprehensive Insights
As of February 2024, the financial valuation metrics for the company reveal critical investment insights.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -12.45 |
| Price-to-Book (P/B) Ratio | 1.83 |
| Enterprise Value/EBITDA | -6.72 |
| Current Stock Price | $3.57 |
Stock price performance analysis demonstrates significant volatility:
- 52-week low: $2.14
- 52-week high: $5.89
- Price change in last 12 months: -39.22%
Analyst recommendations breakdown:
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 44.4% |
| Sell | 22.3% |
Dividend metrics are currently not applicable for this company.
Key Risks Facing Inhibrx, Inc. (INBX)
Risk Factors Impacting Financial Health
As of the latest financial reporting, the company faces several critical risk factors that could significantly influence its financial performance and investor outlook.
Financial and Operational Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Cash Burn Rate | Research and Development Expenses | $83.4 million spent in 2023 |
| Liquidity Risk | Cash and Cash Equivalents | $244.6 million as of Q4 2023 |
| Market Volatility | Stock Price Fluctuation | -62.3% year-to-date performance |
Key Operational Risks
- Clinical Trial Uncertainties
- Regulatory Approval Challenges
- Intellectual Property Protection
- Technology Development Risks
Financial Risk Breakdown
The company's financial risks include:
- Potential funding shortfalls with $83.4 million annual R&D expenditure
- Limited revenue generation with $12.3 million total revenue in 2023
- Ongoing net loss of $97.2 million for the fiscal year
Regulatory and Compliance Risks
| Regulatory Area | Risk Level | Potential Financial Impact |
|---|---|---|
| FDA Approval Process | High | Potential $50-100 million investment required |
| Clinical Trial Compliance | Medium | Potential $20-40 million additional costs |
Market and Competitive Risks
Market positioning remains challenging with:
- Intense competition in biotechnology sector
- Limited product pipeline with 3 primary drug candidates
- High research and development costs
Future Growth Prospects for Inhibrx, Inc. (INBX)
Growth Opportunities
The company's growth potential is anchored in several key strategic areas with specific financial metrics:
| Growth Category | Projected Value | Timeline |
|---|---|---|
| Research & Development Investment | $42.6 million | 2024 Fiscal Year |
| Clinical Pipeline Expansion | 4 Advanced Therapeutic Programs | Next 18 Months |
| Market Potential for Lead Candidates | $1.2 billion | By 2026 |
Key growth drivers include:
- Oncology therapeutic platform with 3 novel antibody programs
- Expanding therapeutic indications across rare disease segments
- Potential strategic collaborations with pharmaceutical partners
Strategic partnership potential highlights:
| Partnership Type | Estimated Value | Potential Impact |
|---|---|---|
| Licensing Agreements | $75-120 million | Near-term Revenue Acceleration |
| Research Collaborations | $50 million | Technology Platform Validation |
Competitive advantages positioning future growth:
- Proprietary antibody discovery platform
- Patent portfolio with 18 granted patents
- Innovative therapeutic approach in rare disease treatment
Inhibrx, Inc. (INBX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.